Related by context. All words. (Click for frequent words.) 66 assessing T DM1 65 Pemetrexed 64 SPRYCEL ® 64 cisplatin gemcitabine 64 3 registrational trial 64 Erbitux cetuximab 64 pain palliation 64 relapsed MM 64 Amrubicin 63 trastuzumab Herceptin R 63 novel histone deacetylase 62 Gleevec Glivec 62 Hsp# Inhibitor 62 Myocet 62 Annamycin 62 bevacizumab Avastin ® 62 Camptosar ® 62 ZACTIMA 62 Degarelix 62 Ixempra 62 ® bortezomib 62 novel VDA molecule 62 Neulasta R 62 Aplidin 62 oral deforolimus 62 mCRC 62 Clolar ® 62 CYT# potent vascular disrupting 62 Irinotecan 61 multiple myeloma MM 61 mertansine 61 metaglidasen 61 metastatic CRC 61 Vandetanib 61 docetaxel Taxotere R 61 Fludara ® 61 dasatinib Sprycel 61 YONDELIS 61 Epirubicin 61 Orally administered 61 immunotherapeutic agent 61 INSPIRE Trial Phase III 61 Hormone Refractory Prostate Cancer 61 pan HDAC inhibitor 61 Xeloda ® 61 SCCHN 61 Imprime PGG 61 Panzem R NCD 61 evaluating tivozanib 61 sorafenib tablets 61 metastatic colorectal 61 BR.# 61 mCRC patients 61 biliary tract cancer 61 receptor tyrosine kinase inhibitor 61 IMA# 60 sunitinib malate 60 OMP #M# 60 Pertuzumab 60 IgG1 monoclonal antibody 60 Peginterferon alfa 2b 60 oxaliplatin Eloxatin 60 FOLFOX regimen 60 thalidomide Thalomid 60 lymphoid malignancies 60 huN# DM1 60 pegylated liposomal doxorubicin 60 Tesetaxel 60 Xelox 60 refractory metastatic colorectal cancer 60 Aflibercept 60 hA# 60 ASCO GI 60 Allovectin 7 60 Nexavar ® 60 xenograft models 60 LHRH antagonist 60 Neoadjuvant 60 galiximab 60 Tarceva TM 60 docetaxel Taxotere ® 60 TM Everolimus Eluting 60 MAGE A3 ASCI 60 HepaSphere 60 Gemcitabine 60 Neulasta ® 60 EOquin TM 60 bortezomib Velcade 60 Nexavar sorafenib 60 metastatic colorectal cancer 60 Quinamed 60 novel oral anticoagulant 60 Alkeran 59 Targretin capsules 59 BRIM2 59 Gastrointestinal Stromal Tumors 59 recurrent NSCLC 59 HQK 59 metastatic malignant 59 cediranib 59 5 Fluorouracil 59 Gemzar ® 59 Hedgehog Pathway Inhibitor 59 Phase #b/#a clinical 59 HER2 positive metastatic breast 59 KRAS wild 59 depsipeptide 59 Deforolimus 59 Actimmune ® 59 PKC# 59 cytokine refractory 59 cetuximab Erbitux ® 59 Genentech Rituxan 59 PSMA ADC 59 cetuximab Erbitux R 59 Olmesartan 59 TEMODAL 59 IL# PE#QQR 59 Bosutinib 59 Folfox 59 Zorbtive TM 59 chemotherapy cisplatin 59 estramustine 59 refractory colorectal cancer 59 p# biomarker 59 forodesine 59 tyrosine kinase inhibitor TKI 59 Cloretazine 59 GW# [003] 59 nilotinib Tasigna 59 vidofludimus 59 HuMax EGFr 59 AEG# 59 alvespimycin 59 mitoxantrone plus 59 GetGoal Phase III 59 Apaziquone 59 Xeloda capecitabine 59 Bayer HealthCare Onyx Pharmaceuticals 59 cetuximab Erbitux 59 goserelin 59 SIR Spheres 59 Glufosfamide 59 ORENCIA ® 59 Ophena TM 59 capecitabine Xeloda 59 gastrointestinal stromal tumors GIST 59 sorafenib Nexavar 58 proteasome inhibitor 58 sorafenib Nexavar ® 58 metastatic GIST 58 PNP inhibitor 58 Campath ® 58 ixabepilone 58 Cloretazine ® 58 dasatinib Sprycel ® 58 Phase Ib II 58 Prolongs Survival 58 paclitaxel Taxol ® 58 orally administered inhibitor 58 cilengitide 58 gemcitabine carboplatin 58 Telatinib 58 LHRH receptor positive 58 trabectedin 58 REYATAZ R 58 microsphere therapy 58 relapsed refractory multiple myeloma 58 histone deacetylase inhibitor 58 Carfilzomib 58 gemcitabine Gemzar 58 liposomal formulation 58 IRX 2 58 epigenetic therapies 58 Thalomid ® 58 Brentuximab Vedotin SGN 58 Azedra 58 regorafenib 58 Cetuximab Erbitux 58 paclitaxel carboplatin 58 Vectibix panitumumab 58 Yondelis ® 58 Kepivance 58 Hycamtin ® 58 Randomized Phase 58 erlotinib Tarceva ® 58 docetaxel chemotherapy 58 resminostat 58 rALLy clinical trial 58 Pfizer Sutent 58 Nilotinib 58 IMiD 58 Vidofludimus 58 Metastatic Colorectal Cancer 58 Tanespimycin 58 Coronary stent 58 haematological cancers 58 Dasatinib 58 intravesical infusion therapy 58 Kit CD# positive 58 hepatocellular cancer 58 Aplidin R 58 enzastaurin 58 alefacept 58 haematologic malignancies 58 metastatic colorectal carcinoma 58 budesonide foam 58 OvaRex R 58 CIMZIA ™ 58 ELACYT 58 histone deacetylase HDAC inhibitor 58 plus DOXIL 57 Pazopanib 57 KRAS mutant 57 mRCC 57 plus gemcitabine 57 Proxinium TM 57 Dacogen injection 57 TORISEL 57 HSP# inhibitor 57 dose escalation Phase 57 BrachySil TM 57 Xanafide 57 refractory metastatic 57 Temsirolimus 57 registrational trial 57 KRAS mutations occur 57 essential thrombocythemia ET 57 Camptosar ® irinotecan 57 relapsing multiple sclerosis 57 Etoposide 57 ara C 57 ZOLINZA 57 PANVAC VF 57 concurrent chemoradiation 57 Kissei Pharmaceutical 57 pegfilgrastim 57 fosbretabulin 57 gefitinib Iressa 57 farletuzumab 57 LUX Lung 57 refractory prostate cancer 57 metastatic androgen independent 57 sargramostim 57 PEGylated Fab fragment 57 chimeric monoclonal antibody 57 MGd 57 Torisel 57 Taxotere R 57 Selective Internal 57 tumors GIST 57 Virulizin ® 57 axitinib 57 FOLFIRI alone 57 Ophena 57 BCIRG 57 HuMax CD4 57 targeted radiotherapeutic 57 Omacetaxine 57 AVONEX ® 57 BRAF inhibitor 57 Ozarelix 57 Chronic Lymphocytic Leukemia CLL 57 gemcitabine cisplatin 57 EGFR HER2 57 DCVax ® Brain 57 entinostat 57 cinacalcet 57 CTAP# Capsules 57 oral ridaforolimus 57 familial amyloidotic polyneuropathy FAP 57 rituximab Rituxan 57 Lubiprostone 57 CD# antibody [001] 57 metastatic carcinoma 57 pertuzumab 57 metastatic castration resistant 57 metastatic pancreatic 57 advanced pancreatic neuroendocrine 57 Rebif ® 57 Vascular Wrap TM 57 Cell Lymphoma 57 RECORD1 57 Gleevec imatinib mesylate 57 Interferon alfa 57 liposome injection 57 Biologic Therapy 57 biologic DMARD 57 ACTOS ® 57 folinic acid 57 lumiliximab 57 Navelbine ® 57 CIMZIA TM certolizumab pegol 57 generation NNRTI 57 vinca alkaloid 57 metastatic renal cell 57 acute promyelocytic leukemia APL 57 DCVax R Brain 56 OvaRex ® MAb 56 refractory NSCLC 56 Wafer polifeprosan 56 Taxotere ® 56 Oxaliplatin 56 Immunotherapeutic 56 FOLFIRI 56 Diffuse Large B 56 CML CP 56 Alocrest 56 prostate cancer HRPC 56 vascular disrupting agents 56 Cimzia ® certolizumab pegol 56 platelet inhibitor 56 Parathyroid Hormone 56 Luteinizing Hormone Releasing Hormone 56 Bendamustine 56 biliary cancer 56 Onconase 56 Zarnestra 56 Aptivus ® 56 G#DT 56 Sipuleucel T 56 refractory ovarian cancer 56 demethylating agent 56 Hodgkin lymphoma HL 56 Phase #/#a trial 56 imatinib Gleevec ® 56 Cloretazine R 56 investigational humanized monoclonal antibody 56 Fludara 56 UPLYSO 56 tumor xenograft models 56 radiation sensitizer 56 Dacogen decitabine 56 omacetaxine mepesuccinate 56 Acute Myeloid Leukemia AML 56 MYDICAR ® 56 corticosteroid dexamethasone 56 zoledronic acid Zometa 56 stage IIIb IV 56 intra abdominal abscess 56 Dapagliflozin 56 sitaxsentan 56 Lilly Gemzar 56 RECOTHROM R 56 dacarbazine DTIC 56 Phase 1b clinical trials 56 EGFR TKI 56 Drug eluting stent 56 refractory multiple myeloma 56 Hycamtin 56 etanercept Enbrel 56 nab paclitaxel 56 INC# 56 pancreatic adenocarcinoma 56 refractory CTCL 56 Taxotere docetaxel 56 decitabine 56 Safinamide 56 ritonavir boosted 56 leukemia AML 56 Daclizumab 56 Gleevec resistant 56 Tesmilifene 56 See CLINICAL PHARMACOLOGY 56 radiochemotherapy 56 HGS# 56 Arranon 56 fallopian tube cancers 56 taxane therapy 56 papillary renal cell carcinoma 56 standard chemotherapy regimen 56 alkylating agent 56 imatinib Gleevec 56 elotuzumab 56 MabCampath 56 ON #.Na 56 MIVI TRUST 56 phase IIb clinical 56 SUTENT ® 56 INCB# [001] 56 Doxil ® 56 pegylated interferon alpha 56 oblimersen 56 antibody MAb 56 Oral Fingolimod 56 Sutent sunitinib 56 sunitinib Sutent 56 anticancer agent 56 Kahalalide F 56 paclitaxel Taxol 56 CHOP chemotherapy 56 Soft Tissue Sarcoma 56 Avastin bevacizumab 56 paclitaxel eluting 56 THERMOCOOL R 56 pomalidomide 56 HyperAcute 56 Aryplase 56 multi kinase inhibitor 56 EDEMA3 56 PROSTVAC VF 56 recurrent GBM 56 hepatic tumors 56 FOLFOX6 56 Increlex ® 56 Phase IIIb clinical 56 aflibercept VEGF Trap 56 peritoneal carcinomatosis 56 Velcade bortezomib 56 Ranolazine 56 secondary hyperparathyroidism 56 biologic therapy 56 luteinizing hormone releasing 56 Cardiotoxicity 56 denileukin diftitox 56 recurrent glioblastoma multiforme GBM 55 OHR/AVR# 55 Herceptin trastuzumab 55 adjuvant cisplatin 55 Zoledronic acid 55 androgen independent 55 Taxol paclitaxel 55 advanced hepatocellular carcinoma 55 FOLFOX chemotherapy 55 low dose cytarabine 55 unresectable locally advanced 55 XIAFLEX ® 55 refractory AML 55 Taxol ® 55 ENMD # 55 melphalan prednisone 55 Aloxi R 55 CLL SLL 55 teriflunomide 55 Lenalidomide 55 Hematologic 55 Pharmacokinetics PK 55 Teriflunomide 55 Targretin 55 Rituxan rituximab 55 AQ4N 55 Halaven 55 advanced NSCLC 55 nonsmall cell lung cancer 55 recurrent glioblastoma 55 Paraplatin ® 55 Tracleer R 55 lorvotuzumab mertansine 55 Cimzia TM 55 Phase Ib study 55 CRLX# 55 Delcath Phase III 55 mitomycin 55 recurrent colorectal cancer 55 Clinical Trial Results 55 PROSTVAC ® 55 tyrosine kinase inhibitor 55 ASH Annual Meeting 55 paclitaxel Taxol R 55 fallopian tube carcinoma 55 somatostatin analog 55 metastatic neuroendocrine tumors 55 metastatic renal cell carcinoma 55 EndoTAG 55 unresectable liver cancer 55 Pirfenidone 55 huC# DM4 55 TRISENOX 55 phase IIb trial 55 Systemic Sclerosis 55 anti angiogenic therapy 55 cancer mCRC 55 VEGF inhibitor 55 ADXS# 55 HDAC Inhibitor 55 KRAS status 55 docetaxel Taxotere 55 Hematological Malignancies 55 delafloxacin 55 relapsed multiple myeloma 55 neoadjuvant treatment 55 taxotere 55 Insegia 55 Malignant Melanoma 55 ASCO abstract 55 mSEPT9 55 cisplatin resistant 55 PEG SN# 55 gastric adenocarcinoma 55 Genasense ® 55 unresectable tumors 55 Tyrima 55 Loramyc R 55 Fludarabine 55 cutaneous T 55 selective modulator 55 recurrent metastatic 55 Troxatyl 55 gemcitabine Gemzar ® 55 Anticancer Drug 55 miconazole Lauriad ® 55 allogeneic HSCT 55 TTF Therapy 55 systemic ALCL 55 Renal Cell Carcinoma RCC 55 LEUKINE 55 bevacizumab Avastin 55 trabedersen 55 thymidylate synthase TS 55 Preclinical Models 55 Ranibizumab 55 relapsing remitting MS RRMS 55 atypical Hemolytic Uremic Syndrome 55 vincristine doxorubicin 55 CANCIDAS 55 plasma kallikrein inhibitor 55 xanthine oxidase inhibitor 55 NSABP 55 daunorubicin 55 angiogenesis inhibitor 55 biotherapy 55 Tarceva erlotinib 55 NCIC CTG 54 crizotinib PF # 54 stage IIIb 54 gemcitabine chemotherapy 54 irinotecan chemotherapy 54 Fluorouracil 54 prostate carcinoma 54 Vicinium TM 54 gastrointestinal stromal tumors GISTs 54 Myelodysplastic Syndrome MDS 54 KSP inhibitor 54 intravesical instillation 54 Epratuzumab 54 Sapacitabine 54 Multiple Myeloma MM 54 Squalamine 54 Alexion Soliris 54 cisplatin vinorelbine 54 selective agonist 54 antiangiogenic agent 54 HRPC 54 infusional 5-FU/LV 54 mTOR inhibitors 54 Raptiva ® 54 PARP inhibitor 54 Pralatrexate 54 Capecitabine 54 interferon beta therapy 54 Navelbine 54 CALGB # [002] 54 cell lymphoma CTCL 54 ibritumomab tiuxetan 54 glufosfamide 54 hepatocellular carcinoma HCC 54 ceftazidime 54 Relapsed Refractory 54 Hepatocellular Carcinoma HCC 54 Vfend 54 MEND CABG II 54 Surgical Sealant 54 #I TM# 54 Monoclonal antibody 54 NSABP B 54 Peginterferon 54 ErbB2 positive 54 bendamustine 54 Anthracycline 54 Hematology Meeting 54 adecatumumab 54 elacytarabine 54 PecFent 54 potentially hepatotoxic 54 PROMUS Element Stent 54 interstitial brachytherapy 54 dexamethasone Decadron 54 amrubicin 54 Artelon ® 54 tigecycline 54 Decitabine 54 Exemestane 54 oral JAK1 54 Trabectedin 54 Hematologic Oncology 54 pediatric acute lymphoblastic 54 Ontak 54 non metastatic osteosarcoma 54 vemurafenib 54 Eltrombopag 54 relapsed ovarian cancer 54 APTIVUS 54 doublet chemotherapy 54 antitumor effect 54 mycophenolate mofetil 54 Fulvestrant 54 liposomal doxorubicin 54 Gefitinib 54 EGFR mutant 54 antiplatelet agent 54 fluoropyrimidine 54 Voreloxin 54 mapatumumab 54 TheraSphere 54 Surgical resection 54 iniparib 54 invasive candidiasis 54 FOLFOX4 54 Pegylated Liposomal Doxorubicin 54 prostate cancer mCRPC 54 IV Busulfex 54 inhibitor RG# 54 Amplimexon 54 CA4P 54 epirubicin cyclophosphamide 54 etoposide 54 RLY# 54 Taxotere chemotherapy 54 Zemplar 54 OZURDEX ® 54 BARACLUDE ® 54 malignant ascites 54 XmAb# 54 Pegylated Interferon 54 vorinostat 54 Novartis Gleevec 54 Aclasta 54 systemic antifungal 54 Onco TCS 54 velafermin 54 doxorubicin cyclophosphamide 54 fluvastatin 54 RRM1 54 RESTYLANE 54 nonmetastatic 54 Tacrolimus 54 antithrombotics 54 Ambrisentan 54 azacitidine 54 PRT# 54 Ethyol 54 Bortezomib 54 PI3K inhibitor 54 Glioblastoma Multiforme 54 epithelial tumors 54 Myelodysplastic Syndromes 54 XIENCE V PROMUS Stent 54 Seliciclib 54 CTRC AACR San Antonio 54 Hepatocellular Carcinoma 54 Copegus ribavirin 54 VALSTAR 54 Azixa 54 Bezielle 54 phase IIb study 54 microcoil 54 CALGB 54 brentuximab vedotin SGN 54 rilonacept 54 Factor VIIa 53 posaconazole 53 transarterial 53 YERVOY 53 breast cancer subtypes 53 SSc 53 Sorafenib 53 Myelofibrosis 53 EGFR mutation positive 53 Group RTOG 53 PXD# 53 NOD SCID mice 53 Talabostat 53 ChronVac C ® 53 ibandronate 53 olmesartan 53 Ceflatonin 53 adriamycin 53 SANTE 53 dose escalation clinical 53 afatinib 53 generation cephalosporin 53 ISTODAX 53 refractory CLL 53 Bevacizumab 53 Kevetrin ™ 53 metastatic HRPC 53 EGFR expressing 53 TNF alpha inhibitor 53 metastatic hormone refractory 53 Mycamine 53 non metastatic resectable 53 Ceplene/IL-2 53 EndoTAGTM 1 53 5FU 53 AASLD Meeting 53 liposomal amphotericin B 53 FOLOTYN 53 romidepsin 53 ZD# [001] 53 trastuzumab Herceptin ® 53 NEUPOGEN 53 alpha folate receptor 53 recurrent malignant glioma 53 BCG refractory 53 NXL# 53 Traficet EN 53 H. pylori eradication 53 fludarabine cyclophosphamide 53 PEG interferon 53 VIDAZA azacitidine 53 Metvix 53 samalizumab 53 Follicular Lymphoma 53 BrachySil ™ 53 VIDAZA 53 glatiramer acetate 53 micafungin 53 abacavir Ziagen 53 interferon ribavirin 53 hepatoma 53 MEK inhibitor 53 clodronate 53 Panzem 53 basiliximab 53 oropharyngeal candidiasis 53 TG MV 53 Eastman Tritan 53 refractory DLBCL 53 HIF PHI 53 gadobutrol 53 Tavocept 53 glioblastoma multiforme GBM 53 Cutaneous T 53 SABCS 53 vandetanib 53 mCRPC 53 Allovectin 7 ® 53 GRASPA ® 53 PEG IFN 53 completely resected 53 commercialize deforolimus 53 anti EGFR antibody 53 Endovascular Graft 53 lintuzumab 53 AP# [003] 53 BioSTAR R 53 anthracycline taxane 53 CAELYX 53 Tyrosine Kinase Inhibitors 53 IMC A# 53 PD LID 53 doxorubicin HCl liposome injection 53 5 fluorouracil 53 Eli Lilly Gemzar 53 carcinoid tumors 53 DOXIL ® 53 OPAXIO 53 bacillus Calmette Guerin 53 MDS AML 53 meropenem 53 cholangiocarcinoma 53 prucalopride 53 recurrent glioblastoma multiforme 53 CR nPR 53 IRESSA 53 anti angiogenic agent 53 drug Treanda 53 recurrent squamous cell carcinoma 53 orally bioavailable 53 Targeted Anticancer Therapies 53 Papillary 53 locoregional recurrence 53 CD# monoclonal antibody 53 refractory chronic myeloid 53 marketed pegylated interferons 53 medullary thyroid cancer 53 HGS ETR1 53 Neuradiab 53 XL# SAR# 53 Gleevec imatinib 53 postoperative chemotherapy 53 RAV# 53 satraplatin Phase 53 gastrointestinal stromal tumor GIST 53 Filgrastim 53 Crit Rev 53 myeloproliferative disorders 53 PROSTVAC TM 53 Phase Ib clinical 53 prostate cancer CRPC 53 INCB# [003] 53 TYKERB 53 cisplatin chemotherapy 53 TACI Ig 53 SERMs 53 follicular lymphoma FL 53 histological subtype 53 NMIBC 53 targeting CD# 53 TREANDA 53 pancreatic NET 53 Metastatic Renal Cell Carcinoma 53 RhuDex ® 53 mTOR inhibitor 53 dosing cohort 53 temozolomide 53 VFEND 53 Tracleer r 53 riociguat 53 Folotyn 53 Erlotinib 53 multicenter prospective 53 Treanda 53 amifostine 53 ToGA 53 Trastuzumab 53 pitavastatin 53 polycythemia vera essential thrombocythemia 53 basal cell carcinoma BCC 53 Mitoxantrone 53 superficial bladder cancer 52 platinum refractory 52 Sudhir Agrawal D.Phil 52 castrate resistant 52 clinicopathological features 52 Mantle Cell Lymphoma 52 gemtuzumab ozogamicin 52 patientswith 52 pegylated interferons 52 HER2 + 52 vinorelbine 52 chemo resistant 52 Natalizumab 52 pancreatic neuroendocrine tumors 52 MGuard ™ 52 K RAS 52 verteporfin 52 imatinib resistant 52 panitumumab Vectibix 52 aflibercept 52 unresectable stage 52 recurrent glioma 52 neoadjuvant 52 lymphoma CTCL 52 CRp 52 Carboplatin 52 IMC #B 52 hormone refractory prostate cancer 52 PegIFN 52 Advexin 52 Leukemias 52 Philadelphia Chromosome Positive 52 receptor blocker 52 breast carcinoma 52 carboplatin paclitaxel 52 relapsed CLL 52 azacytidine 52 diarrhea predominant irritable 52 Gastrointestinal Cancers Symposium 52 Lymphoseek ® 52 ZYBRESTAT TM 52 Powerlink System 52 antiangiogenic therapy 52 Vectibix 52 metastatic gastric 52 mechanical thrombectomy 52 randomized Phase IIb 52 masitinib 52 temsirolimus 52 Antitumor activity 52 lenalidomide Revlimid R 52 ribavirin RBV 52 Capsulution 52 ONX 52 Everolimus 52 colorectal adenocarcinoma 52 immunomodulatory therapy 52 ductal adenocarcinoma 52 TheraSphere R 52 noninfectious uveitis 52 pancreatic islet cell 52 cutaneous T cell 52 vismodegib 52 acute myeloid 52 complete cytogenetic response 52 Oncotype DX ® 52 HYCAMTIN 52 STENT 52 HPAPIs 52 Everolimus Eluting Coronary Stent 52 urothelial cancer 52 skeletal metastases 52 ENESTnd 52 HCV Protease Inhibitor 52 5-FU/LV 52 mycophenolate mofetil MMF 52 Surgical Mesh 52 STARFlex R 52 indibulin 52 BEXXAR Therapeutic Regimen 52 syngeneic 52 trans retinoic acid 52 octreotide LAR 52 palliative radiotherapy 52 SUTENT 52 relapsed leukemia 52 Talent Abdominal 52 JAK inhibitor 52 Tarsa oral calcitonin 52 Cytoxan 52 ALN TTR 52 trastuzumab Herceptin 52 anthracyclines taxanes 52 pancreatic carcinoma 52 prostate cancer PCa 52 metastatic bladder 52 bexarotene 52 interferon alfa 52 Tamibarotene 52 Asentar 52 intravenous belinostat 52 beta lactamase inhibitor 52 European CanCer Organisation 52 taxane chemotherapy 52 Epidermal Growth Factor Receptor 52 OXi# 52 Castration Resistant Prostate Cancer 52 urothelial carcinoma 52 imatinib mesylate Gleevec 52 milatuzumab 52 ABCSG 52 ADI PEG 52 fistulizing Crohn disease 52 carfilzomib 52 gemcitabine 52 tolevamer 52 BIBW 52 oral clodronate 52 Clevudine 52 cetuximab 52 NSCLC 52 transthyretin amyloidosis 52 efalizumab 52 Aloxi injection 52 chemotherapeutic regimen 52 Cancer Res 52 EndoTAG TM -1 52 Hematology Molecular Pathology 52 dose melphalan 52 Paraplatin ® carboplatin 52 ganetespib 52 OMAPRO 52 colorectal carcinoma 52 Powerlink ® 52 Peg IFN 51 tumor metastases 51 5alpha reductase 51 chronic lymphocytic leukemia CLL 51 Clinical Oncology Annual Meeting 51 Betaferon ® 51 papillary RCC 51 indolent NHL 51 MVA MUC1 IL2 51 Kinoid 51 squamous cell carcinoma SCC 51 renal cell carcinoma 51 liver metastasis 51 ovarian carcinoma 51 GVAX Pancreas Vaccine 51 Chronic Lymphocytic Leukemia 51 Albuferon TM 51 BAY #-# 51 NeoRecormon 51 CR# vcMMAE 51 ACTICOAT 51 generation cephalosporins 51 ABVD 51 resistant ovarian cancer 51 TLR antagonist 51 FTY# fingolimod 51 acute HAE attacks 51 OncoVEX GM CSF 51 SAFLUTAN 51 nilotinib 51 talabostat 51 Oncology ASTRO 51 stage IIIB IV 51 Tasigna nilotinib 51 IV malignant melanoma 51 IMGN# 51 autologous SCT 51 TMC# r 51 Denufosol 51 Arixtra 51 NANOTECH 51 HCV SPRINT 51 TRC# 51 locoregional disease 51 achieved CCyR